Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Late-Stage Trials for Depression and Anxiety

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on novel serotonergic agonists (NSAs), announced that Interim CEO Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026. The discussion, scheduled for 2:35 p.m. EDT, will be webcast live and later available on the company’s investor relations website. This appearance signals the company’s efforts to update the investment community on its pipeline, which includes two late-stage candidates addressing major depressive disorder (MDD) and generalized anxiety disorder (GAD).

The company’s lead program, HLP003, is in Phase 3 clinical development as an adjunctive treatment for MDD and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Breakthrough Therapy Designation is intended to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions. HLP003 is a proprietary NSA designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering durable improvements in mental health. If successful, HLP003 could address the large unmet need for patients who do not respond adequately to standard antidepressants.

Additionally, Helus Pharma is developing HLP004, another proprietary NSA, which is in Phase 2 trials for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs. The focus on synthetic molecules that target serotonin receptors differentiates Helus Pharma from other psychedelic-inspired therapies, aiming for efficacy without the hallucinogenic effects often associated with classic psychedelics.

The Jefferies Global Healthcare Conference is one of the largest industry gatherings, attracting investors, analysts, and biotech executives. Helus Pharma’s participation provides a platform to discuss clinical data and regulatory strategies. The company’s interim CEO, Eric So, is expected to highlight the potential of NSAs to improve the treatment landscape for depression and anxiety, conditions that affect millions worldwide.

Helus Pharma, operating under the commercial name Cybin Inc., was founded in 2019 and has operations in Canada, the United States, the United Kingdom, and Ireland. The company’s proprietary NSAs are intended to provide durable improvements in mental health by promoting neuroplasticity. For more information, the full press release is available at https://ibn.fm/1QdP7. Investor updates can also be found on the company’s newsroom at https://ibn.fm/HELP.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Late-Stage Trials for Depression and Anxiety.

The post Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Late-Stage Trials for Depression and Anxiety appeared first on citybuzz.